Creo Medical Group plc

("Creo", the "Company" or the "Group")

First UK private hospital use Speedboat for colorectal cancer case

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, notes the announcement from The London Clinic, one of the UK's leading private hospitals, which confirms that it has successfully launched the Speedboat procedure for early colorectal cancer.

The announcement is available here https://www.thelondonclinic.co.uk/news-articles/london-clinic-performs-first-ever-speedboat-submucosal-dissection-for-early-colorectal-cancer and is reproduced below in full:

The London Clinic Performs First-Ever Speedboat Submucosal Dissection for Early Colorectal Cancer

The London Clinic is proud to announce a significant milestone in advanced endoscopic care: Dr Roser Vega has successfully performed the hospital's first-ever Speedboat submucosal dissection (SSD), offering a highly innovative, organ-sparing treatment for patients with early colorectal cancer.

This achievement marks The London Clinic as the first private hospital in the UK to introduce and deliver this cutting-edge technique, reinforcing its commitment to pioneering minimally invasive treatments and improving patient outcomes.

Speedboat submucosal dissection (SSD) is a form of endoscopic submucosal dissection (ESD) performed using the Speedboat® device, an advanced surgical instrument that combines cutting, coagulation, and dissection capabilities in a single tool. The device uses innovative technology developed and manufactured by Creo Medical, enabling clinicians to perform highly precise and controlled removal of early-stage cancerous and pre-cancerous lesions from the gastrointestinal tract.

Unlike traditional surgical approaches, which may require partial removal of the colon, SSD offers a less invasive, organ-preserving alternative. Patients benefit from reduced recovery times, fewer complications, and the potential to avoid major surgery altogether.

Dr Roser Vega, Consultant Gastroenterologist at The London Clinic, commented:

"We are delighted to bring this advanced technique to patients in the private sector. Speedboat submucosal dissection represents a major step forward in the treatment of early colorectal cancer, allowing us to remove lesions effectively while preserving organ function. This approach significantly improves patient experience and outcomes."

The introduction of SSD at The London Clinic reflects the hospital's ongoing investment in innovative technologies and specialist expertise. By offering this service, The London Clinic is expanding access to state-of-the-art, minimally invasive cancer treatments within the UK's private healthcare sector.

This milestone further strengthens The London Clinic's position as a leader in advanced endoscopy and patient-centred care.

The introduction of Speedboat submucosal dissection at The London Clinic reflects continued investment by leading institutions in advanced endoscopic techniques and reinforces Creo Medical's position at the forefront of minimally invasive cancer care. The procedure further expands access to state‑of‑the‑art endoscopic procedures within the UK, supporting broader adoption across both public and private healthcare systems.

This milestone builds on the growing clinical momentum for Speedboat across key geographies and high‑value procedural areas, including complex upper and lower gastrointestinal interventions, and further validates the scalability and relevance of Creo's Advanced Energy platform.

Craig Gulliford, Chief Executive Officer of Creo Medical, commented:

"The successful launch of the Speedboat service at The London Clinic is a significant endorsement of our technology and its role in delivering organ‑sparing, minimally invasive cancer treatments in a private healthcare setting here in the UK. Adoption by a leading private hospital highlights the growing clinical confidence in Speedboat, reinforcing our belief that advanced endoscopic products like ours will play an increasingly important role in improving both the clinical outcomes for patients and the accessibility of these procedures. We are delighted to see Speedboat continuing to expand its footprint across centres of excellence and delivering meaningful benefits for both clinicians and patients."

For further information please contact: 

About Creo Medical - www.creomedical.com

Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.

About The London Clinic - www.thelondonclinic.co.uk

The London Clinic is one of the UK's leading private hospitals, delivering world-class care across a range of specialties. With a focus on innovation, clinical excellence, and patient wellbeing, the hospital continues to pioneer advanced treatments and technologies to improve healthcare outcomes.